Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


'Uncomfortable' Panel Backs Amgen Biosimilar, But Uphill Battle To Sway Docs, Public

Executive Summary

A tense advisory committee meeting, where many of the panelists admitted they lacked a complete understanding about biosimilars and patient advocates expressed anxiety over the products, could signal difficulties with adoption and success in the marketplace.


Related Content

Amgen Plugs Away On Repatha, With Hope For New Monthly Product
Samsung Seeks Third Anti-TNF Biosimilar Launch In Europe
Japan Rebound For Amgen With Daiichi Biosimilars Deal
Sandoz Climbs 'Pyramid' To Reach Biosimilar Success
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Enbrel Biosimilar Market In Sandoz's Grasp; Will Cost, Litigation Derail It?
Courts, Not FDA Panel, Likely Bigger Hurdle For Amgen's Humira Biosimilar
Humira Biosimilar Under Review: Amgen, AbbVie Tango Time
US Capitol Capsule: Biosimilars Uptake Will Fail Without Trust, Accountability


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts